Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 186Re-Bivatuzumab in Breast Adenocarcinoma
NCT02204046Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2000
- Primary completion
- Feb 2001
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label, single-arm trial of bivatuzumab in breast adenocarcinoma, sponsored by Boehringer Ingelheim. Primary endpoints: Number of patients with adverse events up to 6 weeks, Number of patients with abnormal changes in laboratory parameters up to 6 weeks and 8 more. Started Jan 2000; status: completed.
02
Drugs
bivatuzumab
03
Conditions
breast adenocarcinoma
Beyond the preview
Go deeper on NCT02204046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204046.